Humana (NYSE:HUM) Stock: Insider Joseph Ventura Sells 5,495 Shares

Humana Inc. (NYSE:HUM) insider Joseph Ventura sold 5,495 shares of Humana stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the completion of the sale, the insider owned 21,910 shares of the company’s stock, valued at approximately $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Humana Stock Performance

Shares of Humana stock traded down $3.91 during mid-day trading on Thursday, hitting $442.40. 276,570 shares of the stock were exchanged, compared to its average volume of 1,645,875. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $456.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.74 and a current ratio of 1.65. The company has a 50-day simple moving average of $406.79 and a 200 day simple moving average of $314.80. The company has a market capitalization of $53.13 billion, a P/E ratio of 42.93, a P/E/G ratio of 2.30 and a beta of 0.65.

Humana (NYSE:HUM) last posted its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. During the same quarter in the prior year, the company earned $3.24 EPS. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. Sell-side analysts anticipate that Humana Inc. will post 9.56 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a $0.8850 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s payout ratio is 34.44%.

Key Humana News

Investors following HUM have been watching these news items:

• Positive Sentiment: Zacks Research upgraded Humana to Strong Buy, citing improving earnings prospects. A separate report also noted a fair-value increase following the company’s star-rating update and third-quarter results. Zacks Strong Buy upgrade Fair-value assessment
• Positive Sentiment: JPMorgan raised its price target to $484 from $393 while maintaining a Neutral rating, and a separate report said the bank sees Humana’s shares as positioned to rise. The higher target adds to favorable post-earnings analyst attention. JPMorgan view on Humana shares
• Positive Sentiment: Humana’s new oncology-care model with Evolent and American Oncology Network aims to streamline cancer treatment by reducing prior-authorization hurdles. The initiative may support its broader value-based-care strategy, though its financial impact is not yet clear. Oncology model analysis

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on HUM shares. Deutsche Bank assumed coverage on Humana in a research report on Thursday, July 30th. They set a “hold” rating on the stock. Piper Sandler increased their target price on Humana from $463.00 to $526.00 and gave the stock an “overweight” rating in a research note on Monday. Weiss Ratings upgraded Humana from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, August 14th. Monness Crespi & Hardt upgraded Humana to a “buy” rating in a research note on Friday, October 9th. Finally, Raymond James Financial reiterated an “outperform” rating on shares of Humana in a research note on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $476.52.

Institutional Trading of Humana

Several large investors have recently added to or reduced their stakes in HUM. BlackRock Inc. acquired a new stake in Humana during the second quarter worth about $4,138,160,000. State Street Corp grew its stake in shares of Humana by 1.6% in the 3rd quarter. State Street Corp now owns 5,543,942 shares of the insurance provider’s stock valued at $2,115,402,000 after buying an additional 86,870 shares during the period. Pzena Investment Management LLC acquired a new position in Humana in the second quarter valued at approximately $1,749,014,000. Assenagon Asset Management S.A. grew its position in Humana by 20,126.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock worth $479,053,000 after acquiring an additional 1,249,272 shares during the period. Finally, Legal & General Group Plc purchased a new position in Humana in the second quarter worth approximately $329,760,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.